原发性甲状腺淋巴瘤研究进展

Advances in Primary Thyroid Lymphoma

原发性甲状腺淋巴瘤(PTLs)与甲状腺自身免疫反应密切相关,其分子发生机制目前尚不十分清楚。提高PTLs良恶性的分辨能力仍是亟待解决的问题,现已有部分分子生物学手段应用于临床诊断。PTLs的治疗和预后与其组织学特征、病理分类及临床分期密切相关,随着淋巴瘤分类、分期、分级以及国际预后索引标准的不断明确和细化,甲状腺淋巴瘤个性化治疗已成为可能。

Primary thyroid lymphomas （PTLs） are closely correlated with the autoimmune reaction of thyroid. However, the molecular mechanisms of PTLs are still unclear. It is really necessary to improve the ability to differentiate between benign and malignant PTLs along with the introduction of some new molecular biology methods. The diagnosis and prognosis of PTLs depend on their histological features, pathological classification, and clinical stages. Customized therapy of PTLs becomes possible with the further advances in lymphoma＇s pathological classification, clinical stages, and international prognosis index standard.